Biocept, Inc.

NasdaqCM:BIOC Rapport sur les actions

Capitalisation boursière : US$2.7m

Biocept Bilan de santé

Santé financière contrôle des critères 2/6

Biocept has a total shareholder equity of $290.0K and total debt of $526.0K, which brings its debt-to-equity ratio to 181.4%. Its total assets and total liabilities are $22.1M and $21.8M respectively.

Informations clés

181.4%

Ratio d'endettement

US$526.00k

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$6.63m
Fonds propresUS$290.00k
Total du passifUS$21.81m
Total des actifsUS$22.10m

Mises à jour récentes de la santé financière

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23
Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19
Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03
Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13
Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Jan 26
We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Dec 22
Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Nov 20

Biocept +4% on COVID-19 testing update

Nov 12

Analyse de la situation financière

Passif à court terme: BIOC's short term assets ($8.9M) exceed its short term liabilities ($4.9M).

Passif à long terme: BIOC's short term assets ($8.9M) do not cover its long term liabilities ($16.9M).


Historique et analyse du ratio d'endettement

Niveau d'endettement: BIOC has more cash than its total debt.

Réduire la dette: BIOC's debt to equity ratio has increased from 20% to 181.4% over the past 5 years.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: BIOC has less than a year of cash runway based on its current free cash flow.

Prévisions de trésorerie: BIOC has less than a year of cash runway if free cash flow continues to grow at historical rates of 15.3% each year.


Découvrir des entreprises saines